Goldman Sachs analyst Terence Flynn maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $246 to $436.
Explained: Russian Ruble Hits Strongest Level In 7 Years Against US Dollar Despite Western Sanctions
Withstanding severe western trade sanctions against Kremlin, the Russian Ruble has hit a seven-year high against the U.S. dollar.
